A to Z

Ozempic

·July 15, 2024·5 min read

Adjusting Proteins Increases Ozempic’s Effectiveness

Adjusting melanocortin proteins in the brain enhances the effectiveness of GLP-1 diabetes and weight-loss drugs. By inhibiting MC3R or activating MC4R, mice showed increased sensitivity to these drugs, leading to more significant weight loss and reduced feeding without additional side effects.

This shows a woman holding her head in pain.

Featured Neurology Neuroscience

·March 2, 2026·7 min read

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Unexpected relief. New research shows that patients taking GLP-1 drugs for diabetes or weight loss also experience fewer emergency room visits and need fewer medications for their chronic migraines.

Featured Neuroscience

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

This shows a woman on a scale with people pointing at her.

Featured Neuroscience Psychology

·April 17, 2026·8 min read

Decoding the Shame Associated with Ozempic Weight Loss

Women using GLP-1 drugs for weight loss face higher levels of stigma than those using diet and exercise, with many critics viewing the medication as a "shortcut."

This shows the outline of a person and a brain.

Featured Neuroscience

·January 20, 2025·6 min read

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including reduced risks of addiction, Alzheimer’s, and dementia. However, they also pose risks for pancreatitis and kidney conditions, emphasizing the need for careful monitoring.

This shows a brain made of gut bacteria.

Featured Neuroscience Psychology

·June 10, 2026·9 min read

GLP-1 Drugs Reduce Depression, Boost Stress-Calming Gut Bacteria

The GLP-1 agonist liraglutide treats depressive symptoms via a novel microbial pathway.

Featured Neurology Neuroscience

·April 23, 2026·8 min read

GLP-1 Drugs Target the Roots of Dementia

A comprehensive review of 30 studies finds that GLP-1 receptor agonists are effective at tackling the biological drivers of Alzheimer’s disease.

This shows a person running and a brain.

Featured Neuroscience

·June 13, 2026·8 min read

GLP-1 Therapies Silence Spontaneous Physical Activity

A new study demonstrates that adults managing obesity significantly decrease their physical activity after starting GLP-1 receptor agonist medications.

Featured Neuroscience Psychology

·July 16, 2026·13 min read

GLP-1’s Reduce Binge Eating Symptoms

A new study establishes that GLP-1 receptor agonists significantly reduce core behavioral markers of Binge Eating Disorder, including active binge episodes, loss-of-control eating, and emotional eating.

Featured Neurology Neuroscience

·June 14, 2026·11 min read

GLP-1s Linked to Low Blood Pressure and Fainting Spikes

Adults taking GLP-1 receptor agonists alongside multiple blood pressure medications experience a significant increase in hypotensive events, including severe dizziness, fainting, and falls.

Featured Neuroscience Visual Neuroscience

·July 14, 2026·10 min read

GLP-1s Linked to Sudden, Rare Vision Loss

Researchers identifies a slight statistical association between GLP-1 receptor agonists (including semaglutide and tirzepatide) and an increased risk of ischemic optic neuropathy.

Featured Neuroscience Psychology

·September 4, 2024·5 min read

No Link Found Between Ozempic and Suicide Risk

A new study has found no evidence that GLP-1 analogues, common diabetes drugs, increase the risk of suicide, self-harm, or related mental health issues. Researchers analyzed data from around 300,000 people treated with these medications and found no clear link between the drugs and mental health risks.